Chris Viehbacher, Biogen CEO (Photographer: Scott Eells/Bloomberg via Getty Images)

April 25, 2023 07:29 AM EDTUpdated 01:18 PM

Updated: Biogen chops certain stroke and RNA therapy programs as it continues R&D revamp

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Biogen plans to scrap three clinical programs and “deprioritize” preclinical gene therapy and ophthalmology programs as part of CEO Chris Viehbacher’s larger strategy to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Biogen chops certain stroke and RNA therapy programs as it continues R&D revamp

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

AstraZeneca CEO reaffirms commitment to China following executive's detention

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Up­dat­ed: Bio­gen chops cer­tain stroke and RNA ther­a­py pro­grams as it con­tin­ues R&D re­vamp

Senior Reporter

News Reporter

Sign up to read this article for free.

Updated: Biogen chops certain stroke and RNA therapy programs as it continues R&D revamp